GATAD2B

Across TCGA pan-cancer cohorts, GATAD2B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GATAD2B data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GATAD2B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GATAD2B expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where GATAD2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.952	0.697	.002	21	view →
HNSC	DFS	Quartile	IV	0.550	0.919	.001	21	view →
CCRCC	OS	Quartile	III,IV	0.982	0.709	.018	7	view →
GBM	OS	Quartile	All	0.613	0.280	.008	2	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.892	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GATAD2B–LUAD (OS)

Open the LUAD breakdown →